Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany, with the help of Prof. Dr. Peter Seeberger and Dr. Oren Moscovitz.
We strive to develop novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs).
TACAs are attractive targets for novel immunotherapeutics against human cancers. Many TACAs are expressed during embryonic development but not under physiologic conditions in differentiated tissues. On tumors, in contrast, TACAs show very high expression levels, allowing to bring more therapeutic agents to the cancer cell.
Our pipeline comprises several first-in-class assets targeting different TACAs across multiple solid human cancers.
Assets in our pipeline are amenable to various treatment modalities, including antibody-drug conjugates, T cell engagers and others.
Part of our team will be engaging in great scientific conversations at ESMO 2024 in Barcelona, from September 13-17. If you're attending, be sure to connect with @Matthias to learn about our latest advancements!
#ESMO24 #Science #Medicine #Oncology #Tacalyx
Our scientific team will present two posters at ENA 2024 in Barcelona (October 23-25)! 🎉 Will you be attending? If so, don’t miss the chance to meet @Wiebke and @Gustavo as they showcase our latest advancements and technologies!
Dr. Oren Moscovitz has been awarded €25,000 by the Max Planck Society for his promising research toward treatments and non-invasive diagnostics for cancer, which could potentially reduce overall cancer-related deaths. Moscovitz and his team exploit unique sugar patterns found on cancer cells and develop ultra-small antibodies from alpacas (known as nanobodies) that bind to these sugars.
https://www.mpikg.mpg.de/6834320/hermannneuhaus-prize-for-moscovitz?c=132305
We are a growing team of highly motivated scientists. We endorse the biotech spirit of problem solving and let the best idea win. Being innovative and focused is key to have fast decisions and optimized solutions for our early pipeline.
Located in one of Berlin's prestigious science hubs, we offer a vibrant research environment at the forefront of antibody drug development.
Please follow the link for current job offers.
Unsolicited applications are welcome!